Processa PharmaceuticalsPCSA
13F holders, Q1 2024 (March 31)11holders
$2.36avg. 13F price*
At the end of Q1 2024, 11 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings. The largest holders were Sabby Management, LLC ($115K), Vanguard Group Inc. ($58K) and Two Sigma Investments, LP ($57K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 12 | $251K |
| Exits | 0 | $0 |
Ownership 11 holders
| Sabby Management, LLC | 0.83% | New | 48,601 | $115K |
| Vanguard Group Inc. | 0.00% | New | 24,433 | $58K |
| Two Sigma Investments, LP | 0.00% | New | 24,096 | $57K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 4,505 | $11K |
| UBS Group AG | 0.00% | New | 4,181 | $10K |
| Wells Fargo & Company | 0.00% | New | 170 | $402 |
| Bank of America Corp. | 0.00% | New | 160 | $378 |
| Main Street Group, LTD | 0.00% | New | 100 | $235 |
| Allworth Financial LP | 0.00% | New | 85 | $202 |
| Macroview Investment Management LLC | 0.00% | New | 1 | $3 |
| Royal Bank of Canada | 0.00% | New | 4 | $0 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.